Literature DB >> 22909211

Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes.

D J Campbell1, M McGrady, D L Prior, J M Coller, U Boffa, L Shiel, D Liew, R Wolfe, S Stewart, C M Reid, H Krum.   

Abstract

BACKGROUND: A significant proportion of individuals taking antihypertensive therapies fail to achieve blood pressures <140/90 mmHg. In order to develop strategies for improved treatment of blood pressure, we examined the association of blood pressure control with antihypertensive therapies and clinical and lifestyle factors in a cohort of adults at increased cardiovascular risk.
METHODS: A cross-sectional study of 3994 adults from Melbourne and Shepparton, Australia enrolled in the SCReening Evaluation of the Evolution of New Heart Failure (SCREEN-HF) study. Inclusion criteria were age ≥60 years with one or more of self-reported ischaemic or other heart disease, atrial fibrillation, cerebrovascular disease, renal impairment or treatment for hypertension or diabetes for ≥2 years. Exclusion criteria were known heart failure or cardiac abnormality on echocardiography or other imaging. The main outcome measures were the proportion of participants receiving antihypertensive therapy with blood pressures ≥140/90 mmHg and the association of blood pressure control with antihypertensive therapies and clinical and lifestyle factors.
RESULTS: Of 3623 participants (1975 men and 1648 women) receiving antihypertensive therapy, 1867 (52%) had blood pressures ≥140/90 mmHg. Of these 1867 participants, 1483 (79%) were receiving only one or two antihypertensive drug classes. Blood pressures ≥140/90 mmHg were associated with increased age, male sex, waist circumference and log amino-terminal-pro-B-type natriuretic peptide levels.
CONCLUSIONS: Most individuals with treated blood pressures above target receive only one or two antihypertensive drug classes. Prescribing additional antihypertensive drug classes and lifestyle modification may improve blood pressure control in this population of individuals at increased cardiovascular risk.
© 2012 The Authors; Internal Medicine Journal © 2012 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22909211     DOI: 10.1111/j.1445-5994.2012.02927.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  6 in total

Review 1.  Antihypertensive Combination Treatment: State of the Art.

Authors:  M Burnier
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

Review 2.  Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of healthcare interventions in primary care and community settings.

Authors:  Mark E Murphy; Molly Byrne; Rose Galvin; Fiona Boland; Tom Fahey; Susan M Smith
Journal:  BMJ Open       Date:  2017-08-04       Impact factor: 2.692

3.  Development of a complex intervention to promote appropriate prescribing and medication intensification in poorly controlled type 2 diabetes mellitus in Irish general practice.

Authors:  Mark E Murphy; Molly Byrne; Atieh Zarabzadeh; Derek Corrigan; Tom Fahey; Susan M Smith
Journal:  Implement Sci       Date:  2017-09-16       Impact factor: 7.327

Review 4.  The Use of Dried Blood Spots for the Quantification of Antihypertensive Drugs.

Authors:  Alexander Chernonosov
Journal:  Int J Anal Chem       Date:  2018-08-01       Impact factor: 1.885

5.  Supporting care for suboptimally controlled type 2 diabetes mellitus in general practice with a clinical decision support system: a mixed methods pilot cluster randomised trial.

Authors:  Mark E Murphy; Jenny McSharry; Molly Byrne; Fiona Boland; Derek Corrigan; Paddy Gillespie; Tom Fahey; Susan M Smith
Journal:  BMJ Open       Date:  2020-02-12       Impact factor: 2.692

6.  Supporting general practitioner-based care for poorly controlled type 2 diabetes mellitus (the DECIDE study): feasibility study and protocol for a pilot cluster randomised controlled trial.

Authors:  Mark E Murphy; Molly Byrne; Fiona Boland; Derek Corrigan; Paddy Gillespie; Tom Fahey; Susan M Smith
Journal:  Pilot Feasibility Stud       Date:  2018-10-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.